Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

30 Sep 2020 14:27

RNS Number : 6378A
Motif Bio PLC
30 September 2020
 

 

 

Motif Bio plc

 

("Motif Bio" or the "Company")

 

Result of AGM

 

Motif Bio plc (AIM: MTFB) announces that at the Annual General Meeting of the Company held earlier today at the offices of ONE Advisory Limited, 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT all but one of the resolutions put to members were passed on a poll.

 

The Board notes that resolution 7, which was proposed as a special resolution regarding the disapplication of pre-emption rights, was not passed.

 

The number of votes lodged by proxy and voted on by poll for and against each of the resolutions proposed, and the number of votes withheld, were as follows:

 

Resolution

FOR*

%

AGAINST

%

WITHHELD

Resolution 1 (Ordinary)

To receive the Company's annual accounts and the strategic, directors' and auditors' reports for the year ended 31 December 2019.

 

37,371,686

 

91.94

 

 

3,275,355

 

8.06

 

 

131,590

Resolution 2 (Ordinary)

To re-elect Graham Lumsden as a Director of the Company

 

27, 167,596

 

66.74

 

 

13,541,866

 

33.26

 

 

69,169

Resolution 3 (Ordinary)

To re-elect Christopher Wardhaugh as a director of the Company, who was appointed by the board since the last annual general meeting.

 

 

34,740,854

 

 

85.42

 

 

 

5,930,684

 

 

14.58

 

 

 

107,093

Resolution 4 (Ordinary)

To re-appoint the Company's auditor Crowe LLP, who have been appointed by the board since the last annual general meeting.

 

 

37,286,396

 

 

91.56

 

 

 

 

3,437,066

 

 

8.44

 

 

 

55,169

Resolution 5 (Ordinary)

That the Directors be authorised to fix the auditors remuneration.

 

36,844,682

 

 

90.71

 

 

 

3,772,431

 

9.29

 

 

161,518

Resolution 6 (Ordinary)

To empower the directors to allot relevant securities pursuant to Section 551 of the Act

 

33,534,192

 

84.95

 

 

5,941,430

 

 

15.05

 

 

1,303,009

Resolution 7 (Special)

To disapply the pre-emptive rights contained in Section 561 of the Act

 

26,246,162

 

73.09

 

 

 

9,844,855

 

26.91

 

 

4,187,614

 

 

 

*including votes granting discretion to the chair

 

As at 30 September 2020, there were 654,991,023 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

 

 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (President and Chief Business Officer)

 

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

 

+44 (0) 20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0) 20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBXGDCXDXDGGG
Date   Source Headline
7th Mar 201912:07 pmRNSSecond Price Monitoring Extn
7th Mar 201912:02 pmRNSPrice Monitoring Extension
19th Feb 20197:00 amRNSConference Call and Webcast
18th Feb 20197:00 amRNSAmendment Agreement with Hercules Capital
15th Feb 20194:28 pmRNSHolding(s) in Company
15th Feb 20194:26 pmRNSHolding(s) in Company
14th Feb 20197:00 amRNSComplete Response Letter from the FDA
5th Feb 20197:00 amRNSExercise of Warrants
23rd Jan 20194:31 pmRNSExercise of Warrants
1st Nov 20184:40 pmRNSSecond Price Monitoring Extn
1st Nov 20184:35 pmRNSPrice Monitoring Extension
31st Oct 20187:00 amRNSJefferies London Healthcare Conference
30th Oct 20184:35 pmRNSPrice Monitoring Extension
16th Oct 20184:40 pmRNSSecond Price Monitoring Extn
16th Oct 20184:35 pmRNSPrice Monitoring Extension
3rd Oct 20188:01 amRNSMotif Bio Presents New Iclaprim Data at IDWeek
28th Sep 20187:01 amRNSMotif Bio Notes Statement from Amphion Innovations
25th Sep 20187:00 amRNSHalf-year Report
20th Sep 20187:00 amRNSUpcoming Scientific Conferences
5th Sep 20187:00 amRNSIclaprim Data presented at ESCMID/ASM Conference
29th Aug 20184:35 pmRNSPrice Monitoring Extension
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
17th Aug 20187:00 amRNSIclaprim Data at ESCMID/ASM Conference
14th Aug 20184:49 pmRNSHolding(s) in Company
14th Aug 20184:48 pmRNSHolding(s) in Company
14th Aug 20187:00 amRNSFDA Acceptance of New Drug Application
9th Aug 20187:00 amRNSInvestor Events in August and September
8th Aug 20187:00 amRNSNotice of Allowance for Two U.S. Iclaprim Patents
2nd Aug 20184:35 pmRNSPrice Monitoring Extension
3rd Jul 20184:48 pmRNSHolding(s) in Company
3rd Jul 20187:00 amRNSDirectorate Change
26th Jun 201811:57 amRNSExercise of Stock Options
19th Jun 20181:58 pmRNSResult of AGM
14th Jun 20187:00 amRNSMotif Bio Submits NDA for Iclaprim
11th Jun 201811:41 amRNSHolding(s) in Company
11th Jun 20187:00 amRNSMotif Bio present New Iclaprim Data at ASM Microbe
8th Jun 20185:08 pmRNSHolding(s) in Company
31st May 20187:00 amRNSJefferies Global Healthcare Conference
25th May 20184:04 pmRNSHolding(s) in Company
24th May 20184:39 pmRNSHolding(s) in Company
23rd May 20185:42 pmRNSHolding(s) in Company
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
17th May 20182:24 pmRNSResult of Placing
17th May 20189:55 amRNSProposed Placing to raise approximately £10m
9th May 20187:00 amRNSAppointment of Vice President,Clinical Development
8th May 20187:00 amRNSMotif Bio to Present Iclaprim Data at ASM Microbe
1st May 20187:00 amRNSREVIVE-2 Study Results Published in Journal
19th Apr 20187:00 amRNSNew Iclaprim Data being Presented at ECCMID 2018
17th Apr 20184:40 pmRNSSecond Price Monitoring Extn
17th Apr 20184:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.